We are live on ! Find out more
DCOY

Decoy Therapeutics
DCOY

3 hedge funds and large institutions have $19.2M invested in Decoy Therapeutics in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 3 → 3 (0)

0% more ownership

Funds ownership: 0% → 0% (0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

17% less capital invested

Capital invested by funds: $23.2M → $19.2M (-$4.05M)

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
+$3.26M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$3.26M
2
State Street
State Street
Massachusetts
-$612K
3
SIM
Spark Investment Management
New York
-$223K
4
TCIM
TIAA CREF Investment Management
New York
-$146K
5
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS)
California
-$96K

DCOY Hedge Fund Activity: Q2 2017 in Review

3 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q2 2017, worth a combined $19.2M — down 17% from $23.2M a quarter earlier.

Fund positioning in DCOY was balanced in Q2 2017: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was Ameriprise, opening a new position worth an estimated $3.26M. The largest seller was BlackRock, exiting entirely with an estimated $3.26M sold.

  • 3 institutional investors held Decoy Therapeutics (DCOY) as of Q2 2017, unchanged from Q1 2017.
  • Funds reported $19.2M of Decoy Therapeutics stock for Q2 2017, down 17% quarter-over-quarter.
  • 1 fund opened new Decoy Therapeutics positions in Q2 2017 and 1 closed out, a net change of 0 holders.
  • The largest Decoy Therapeutics buyer in Q2 2017 was Ameriprise, an estimated $3.26M added.
  • The largest Decoy Therapeutics seller in Q2 2017 was BlackRock, an estimated $3.26M sold.

Based on aggregated 13F filings for Q2 2017.